Literature DB >> 6130752

Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework.

I M Marks, S Gray, D Cohen, R Hill, D Mawson, E Ramm, R S Stern.   

Abstract

Forty-five chronic agoraphobics were randomly assigned to treatment by placebo or imipramine in doses up to 200 mg/day for 28 weeks. All patients also had systematic self-exposure homework with an instruction manual. In addition, half of each drug group had therapist-aided exposure and half had therapist-aided relaxation, each totalling three hours. Patients in both drug groups improved substantially and maintained their gains for one year of follow-up. Imipramine had no significant therapeutic effect despite satisfactory plasma levels and significant drug side effects. Patients' low initial Hamilton depression scores might explain the absence of any drug effect. Antidepressants may be ineffective for agoraphobics who have normal mood. Brief therapist-aided exposure improved phobias and panics to a significant but limited extent, and is a useful adjuvant to self-exposure homework, which can be a powerful therapeutic agency by itself.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6130752     DOI: 10.1001/archpsyc.1983.01790020047004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  7 in total

Review 1.  Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia.

Authors:  T A Furukawa; N Watanabe; R Churchill
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Panic disorder.

Authors:  I Marks
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-23

3.  Hyperventilation as a cause of panic attacks.

Authors:  G A Hibbert
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

4.  Phobia: prevalence and risk factors.

Authors:  J H Boyd; D S Rae; J W Thompson; B J Burns; K Bourdon; B Z Locke; D A Regier
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1990-11       Impact factor: 4.328

5.  What treatments do patients with panic disorder and agoraphobia get?

Authors:  B Bandelow; K Sievert; M Röthemeyer; G Hajak; E Rüther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

6.  A risk-benefit assessment of pharmacological treatments for panic disorder.

Authors:  J A Bennett; M Moioffer; S P Stanton; M Dwight; P E Keck
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

7.  Nonpharmacological treatments for anxiety disorders.

Authors:  Jean Cottraux
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.